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Abstract
Background:  Eicosanoid receptors are G-protein-coupled receptors playing an important
immunomodulatory role in airway diseases. However, there is little information on the expression
of these receptors and their link with eosinophilic inflammation in paranasal sinus diseases. We
aimed with this study to investigate the tissue expression of leukotrienes and prostaglandin E2
receptors in chronic rhinosinusitis patients and the link of this regulation with eosinophilic
inflammation.
Methods: Samples were prepared from nasal tissue of patients with chronic rhinosinusitis without
nasal polyps (CRS, n = 11), with nasal polyps (CRS-NP, n = 13) and healthy subjects (Controls, n =
6). mRNA expression of CysLT1, CysLT2, BLT1, BLT2, E-prostanoid receptors (EP1, EP2, EP3, EP4)
and sol-IL-5Rα was determined by real-time PCR. Concentrations of PGE2, LTC4/D4/E4, LTB4 and
sol-IL-5Rα were determined by ELISA and of ECP by ImmunoCap. Protein expression and tissue
localization of eicosanoid receptors and activated eosinophils were evaluated by
immunohistochemistry.
Results: CysLT1 mRNA expression was significantly increased in CRS-NP compared to CRS and
controls, and CRS compared to controls, whereas CysLT2 mRNA was enhanced in both CRS
groups without differences between them. Levels of both receptors correlated to the number of
activated eosinophils, sol-IL-5Rα, ECP and LTC4/D4/E4 concentrations in the disease groups. PGE2
protein concentrations and prostanoid receptors EP1 and EP3 were down-regulated in the CRS-NP
tissue vs. CRS and controls, whereas EP2 and EP4 expression was enhanced in CRS and CRS-NP
patients vs. controls. No differences in BLT receptors were observed between patients and
controls.
Conclusion: CyLTs receptors are up-regulated in nasal polyp tissue and their expression correlate
with eosinophilic inflammation supporting previous results. Eicosanoid receptors mRNA pattern
observed suggests that down-regulation of EP1 and EP3 in CRS-NP and up-regulation EP2 and EP4 in
CRS and CRS-NP groups may have some role in the development of the diseases and their
regulation may not be directly linked to eosinophil activation but involve post-transcriptional
events mainly related to other inflammatory cell sources.
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Background
The role of eicosanoids in the pathophysiology of chronic
inflammatory airway diseases has been well documented;
however, the key steps in the regulation leading to the
production of these molecules remain unclear. Eicosa-
noid signalling pathway operates through lipid G-protein-
coupled receptors (GPCRs) [1]. According to the Interna-
tional Union of Pharmacology (IUPHAR), eicosanoid
receptors are classified in four main groups: the BLT recep-
tors, with biological activities related to LTB4, the cysteinyl
leukotrienes (cysLTs) receptors related family, the lipoxin
(ALX) receptors and the prostanoid receptors class [1].
Interaction of cysteinyl leukotrienes receptors (CysLT1 and
CysLT2) with theirs ligand LTC4, LTD4 and LTE4 play a dis-
ease-regulating role in chronic rhinosinusitis/nasal poly-
posis and particularly in the aspirin intolerance syndrome
which is often correlated to these diseases. The biological
actions of these molecules include endothelial cell adher-
ence, myofibroblast proliferation, bronchoconstriction,
vascular hyper-permeability, mucus secretion and chem-
okine production [2]. Immunohistochemical studies have
revealed that the cysLTs receptors are expressed on eosi-
nophils, mast cells, macrophages, neutrophils and vascu-
lar endothelial cells in the nasal mucosa [3]. Expression of
these receptors has been also demonstrated in inflamma-
tory cells in patients with seasonal allergic rhinitis [4]. In
addition, in vitro studies involving cysLTs receptor antago-
nists have also demonstrated the crucial role of these mol-
ecules in the regulation of plasma extravasation and
vascular endothelial growth factor synthesis [5]. These, are
important events involved in the development of oedema
formation in nasal polyps and in the pathogenesis of aller-
gen-induced asthma. Of interest, a recent study performed
in patients with chronic rhinosinusitis/aspirin intolerance
showed that effects of cysteinyl leukotrienes in the nasal
mucosa of these patients seems to occur mainly via inter-
action with CysLT1 on inflammatory leukocytes. However,
effects of these eicosanoids on glands and epithelium may
be mediated predominantly through CysLT2 [6].
Additionally, controversial results about LTB4 and BLT
receptors have been reported in several studies. BLT1 is
expressed primarily in leukocytes, human BLT2 is present
in most human tissues [7,8]. In human peripheral blood
leukocytes, neutrophils and eosinophils express signifi-
cant amounts of both BLT1 and BLT2, whereas mononu-
clear cells express BLT2 but minimal BLT1 [8]. Expression
of BLT receptors can be up-regulated during inflamma-
tion; however, the specific inflammatory stimuli responsi-
ble for their induction have not yet been fully
characterized. In human airways, BLT receptor-LTB4 medi-
ated action play a crucial role in host defence by regulat-
ing processes like recruitment, activation and survival of
cells during inflammation [9-11]. However, until now, no
clear mechanism regulating the synthesis of these mole-
cules in airway has been yet demonstrated.
Finally, the role of prostaglandins in physiology and
immune system is determined by multiple factors such as
cellular context, receptor expression profile, receptor-lig-
and affinity and differential regulation of signal transduc-
tion pathways [12]. The prostanoid receptor subfamily
comprises eight members: the prostaglandin D (DP)
receptor, the prostaglandin E2 receptors (EP1, EP2, EP3 and
EP4), the prostaglandin F receptor (FP), the prostaglandin
I receptor (IP), the tromboxane A receptor (TP), and a
ninth prostaglandin receptor identified recently, the che-
moattractant receptor homologous molecule expressed
on Th2 cells (CRTH2) [12].
In airways, PGE2 may induce bronchodilation and airway
relaxation by acting via EP2 receptor [13,14]. Basal expres-
sion of EP2 and EP4 receptors is increased on bronchial
inflammatory cells from asthmatic patients and may be
altered in vitro on eosinophils in response to inflamma-
tory stimuli, suggesting the immunomodulatory role of
these receptors in asthma, [15]. More recently, a study
comparing EP receptor expression in nasal biopsies from
aspirin intolerant and tolerant patients showed an up-reg-
ulation of EP1 and EP2 in structural cells from aspirin
intolerant subjects [15]. However, in the same study the
number of inflammatory cells expressing EP2 but not EP1,
EP3 or EP4 receptors was significantly up-regulated in the
aspirin intolerant group [15].
Based on the previous studies, we hypothesize that eicosa-
noid receptor expression is altered in chronic rhinosinusi-
tis patients with and without nasal polyposis in absence of
aspirin intolerance and these changes may be related to
eosinophilic inflammation.
Methods
Patients and clinical diagnosis
Samples from ethmoidal and maxillary sinuses were collected
during functional endoscopic sinus surgery (FESS) procedures
in the Department of Otorhinolaryngology at the Ghent Uni-
versity Hospital. Nasal tissues were obtained from 13 patients
with chronic rhinosinusitis and nasal polyposis (CRS-NP) (10
males, 3 females, age range: 30–54 years) and 11 subjects with
chronic rhinosinusitis without nasal polyposis CRS (8 males,
3 females, age range: 21–53 years) who were scheduled for
sinus surgery in the department of Othorinolaryngology of the
Ghent University Hospital. As control group (Controls), we
included 6 subjects (4 males, 2 females, age range: 21–53
years), who underwent septal surgery and removal of parts of
the inferior turbinate due to anatomical variations. These
patients had any acute or chronic clinical, endoscopic or imag-
ing signs of sinusitis or polyposis; and they did not show any
history of atopic, or lower airway disease.Respiratory Research 2006, 7:75 http://respiratory-research.com/content/7/1/75
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Diagnosis of CRS was based on the presence of typical
symptoms (headache, nasal obstruction and discoloured
nasal drainage) longer than 12 weeks and a positive CT-
Scan showing swelling of the ethmoidal and maxillary
mucosa and bilateral obstruction of the osteomeatal com-
plex but without polyp formation, visible during nasal
endoscopy or during surgery. Nasal polyposis was diag-
nosed based on symptoms history (nasal congestion, lost
of smell, changes in sense of taste and persistent postnasal
drainage), clinical examination, nasal endoscopy and
paranasal sinuses CT-Scan, defined as presence of visible
bilateral polyps growing from the middle meatus into the
nasal cavities, and affecting the ethmoidal sinuses. In the
CRS-NP group, three patients had asthma and in the CRS
group, there was one patient with allergic rhinitis and one
with asthma. Diagnosis of asthma was based on clinical
history, typical symptoms and lung (pulmonary) function
tests (Spirometry and Peak Expiratory Flow), following
the Global initiative for asthma (GINA) guidelines. All
patients have taken aspirin or other NSAIDs without man-
ifesting any hypersensitive reaction.
The study was approved by the ethical committee of the
Ghent University Hospital, and all patients gave informed
consent before their participation. The use of any oral
medication with possible impact on measurements of
enzymes or mediators, including systemic glucocorticoids
and anti-leukotrienes, was stopped in all subjects 4 weeks
before surgery. The use of topical glucocorticoids was
interrupted 2 weeks before surgery.
Real time PCR for eicosanoid receptors
Quantitative real time PCR was used to determine the
mRNA levels of eicosanoid receptors. Nasal tissue (30 mg)
was homogenized in Tri-reagent buffer (Sigma-Aldrich,
MO, USA), 1 ml per 50–100 mg of tissue, in a chilled pes-
tle mortar. Total RNA from homogenates was isolated
using Tri-reagent Kit following the manufacturer's instruc-
tions (Sigma-Aldrich, MO, USA). cDNA was synthesized
from 2 µg of total RNA using Oligo(dT)12–18, random hex-
amers and the Superscript RNase H-Reverse Transcriptase
(Life Technologies, CA, USA), as described previously
[16]. Amplification reactions were performed on an iCy-
cler iQ Real-Time PCR Detection System (Bio-Rad labora-
tories, CA, USA) using specific primers (Table 1), designed
with the Primer3 software [17]. PCR reactions contained
20 ng cDNA (total RNA equivalent) of unknown samples,
1X SYBR Green I Master mix (Bio-Rad laboratories, CA,
USA) and 300 nM of primer pairs in a final volume of 25
µl. PCR protocol consisted of 1 cycle at 95°C for 10 min-
utes followed by 45 cycles at 95°C for 30 seconds and at
60°C for 1 minute. The expression of two housekeeping
genes Beta actin (ACTB) and Hydroxymethyl-bilane syn-
thase (HMBS) was used to normalize for transcription and
amplification variations among samples. The relative
number of molecules of each gene, expressed in relative
expression units quantified per 20 ng of cDNA sample,
was determined by the ∆CT value method as described
previously [18].
Eicosanoid levels
Concentration of cysteinyl leukotrienes C4/D4/E4 (LTC4/
D4/E4), prostaglandin E2  (PGE2) and leukotriene B4
(LTB4) were measured by Enzyme Linked Immunoassays
(ELISAs) purchased from Oxford BioMedicals (Oxford,
USA). Sample extraction procedures for protein removal
and eicosanoid stabilization were performed according to
the provider's instructions. Briefly, nasal or sinus tissues
were first homogenized in ethanol (5 ml/g) for LTB4 and
LTC4/D4/E4, and in 15% methanol/0.1 M sodium phos-
phate buffer, pH 7.5 for PGE2 measurements and then
centrifuged for 5 minutes at 3,000 rpm at 4°C. Superna-
tants were diluted in water, pH 3.5 and following manu-
facturer's instructions (Oxford BioMedicals, Oxford,
USA). The detection ranges for all assays were between
0.02–10 ng/ml. The sensitivity was of 0.2 ng/ml for all
assays and the intra-and inter-assay coefficient of varia-
tion less than 10%.
Eosinophil inflammatory markers
Soluble IL-5Rα isoform was quantified using a real time
PCR, as described previously [16]. Briefly, a standard
curve was constructed from a plasmid containing the
cDNA sequence for this receptor isoform. A fragment of
Table 1: Primer sequences used for real time PCR amplification
Eicosanoid 
receptors
Forward primer (5'→ 3') Reverse primer (5'→ 3') Amplicon size Genbank Accession 
number
EP1 GATGGTGGGCCAGCTTGTC GCCACCAACACCAGCATTG 73 bp NM_000955
EP2 GACCGCTTACCTGCAGCTGTAC TGAAGTTGCAGGCGAGCA 73 bp NM_000956
EP3 AAGGCCACGGCATCTCAGT TGATCCCCATAAGCTGAATGG 76 bp NM_000957
EP4 ACGCCGCCTACTCCTACATG AGAGGACGGTGGCGAGAAT 63 bp NM_000958
BLT1 CCTGAAAAGGTGCAGAAGC AAAAAGGGAGCAGTGAGCAA 93 bp NM_000752
BLT2 CTTCTCATCGGGCATCACAG ATCCTTCTGGGCCTACAGGT 88 bp NM_019839
CysLT1 TCCTTAGAATGCAGAAGTCCGTG AAATATAGGAGAGGGTCAAAGCAA 80 bp NM_006639
CysLT2 GCTGATCATTCGGGTTCTGT GGTGATGATGATGGTGGTCA 91 bp NM_020377Respiratory Research 2006, 7:75 http://respiratory-research.com/content/7/1/75
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this plasmid was amplified with specific primers, purified
and used in equimolar 10-fold dilutions to generate a
standard curve. Real time amplifications were performed
in a 25 µl volume reaction containing 1X SYBR Green I
Master mix (Bio-Rad laboratories, CA, USA), 300 nM of
primer pairs and a set of primers specific for this hIL-5Rα
isoform [16]. PCR protocol consisted of 1 cycle at 95°C
for 10 minutes followed by 40 cycles at 95°C for 30 sec-
onds and at 64°C for 1 minute. Each sample was tested in
duplicate. The quantity of each amplicon was calculated
from the values of the standard curve and normalized by
the quantities obtained for beta actin (ACTB) and
hydroxymethyl-bilane synthase (HMBS).
Soluble IL-5α receptor protein concentrations were measured
by a research ELISA as described previously [19] with a sensi-
tivity of 8 pg/ml. and an intra-and inter-assay coefficient of
variation less than 10%. Quantification of Eosinophil Cati-
onic Protein (ECP) was carried out, on supernatants obtained
after nasal tissue homogenization, by the UniCAP system
(Pharmacia & Upjohn, Sweden), with a detection limit of <
0.5 µg/L and a coefficient of variation less than 10%.
The number of activated eosinophils was determined by
staining the eosinophil granulocyte (EG2) and semiquan-
titative scoring of positively stained cells on the different
tissues. For that, frozen tissue sections were fixed in ace-
tone for 10 minutes, washed in TBS buffer and incubated
with (1:1000) mouse anti-human ECP/EPX monoclonal
antibody (Pharmacia & Upjohn Uppsala, Sweden) for 1
hour. Then, the slides were incubated with (1:50) rabbit
anti-mouse IgG for 10 minutes and developed with
(1:100) alkaline phosphatase anti-alkaline phosphatase
(Dako, Glostrup, Denmark) for 10 minutes at room tem-
perature. Signal detection was performed using the New
Fuchsin Substrate System, following the manufacture's
instructions (Dako, Glostrup, Denmark). Semiquantita-
tive scoring was performed by a pathologist, who was
blinded for the clinical data, on a four-point scale adapted
from an already validated system of semiquantitative eval-
uation. Zero represented the lowest and three the highest
score. The analysis included all areas of the biopsies and a
global score was given for each parameter.
Immunohistochemical staining for prostanoid and 
leukotriene receptors
Frozen tissue sections were fixed in acetone for 10 minutes
at room temperature and washed in 1X TBS buffer. Endog-
enous peroxidase activity was blocked with 0.3 % hydro-
gen peroxidase (VWR International, Pennsylvania, USA) in
PBS containing 0,001 % NaN3 for 20 minutes at room
temperature. Sections were than washed for 10 minutes
with 1X TBS and incubated with foetal bovine serum dur-
ing 30 minutes. Sections were then incubated for 1 hour at
room temperature with primary antibodies: rabbit IgG
polyclonal Antibodies for EP1 receptor (1:250), EP2 recep-
tor (1:250), EP3 receptor (1:200), EP4 receptor (1:250),
CysLT1 (1:50) and CysLT2 (1:50), purchased by Cayman
Chemicals (MI, USA). Signal was detected with LSAB+ kit
(HRP Rabbit/Mouse/Goat) purchased from Dako, using
the AEC+ High Sensitivity Substrate Chromogen Kit (Dako,
Glostrup, Denmark). To control for unspecific binding of
the primary antibodies used in the study, parallel stainings
were performed omitting the primary antibody and by
substituting it with an irrelevant antibody or non-immune
sera of the same species (isotype), at the same concentra-
tion as the specific antibody (antisera).
Statistical data analysis
All data was analyzed using the MedCalc software version
6.0 (Mariakerke, Belgium). Results are presented in Box-
and-Whisker plots, where the central box represent the
values from the lower and upper interquartile range, and
the middle line the median. Data comparison within dif-
ferent patient groups was performed using the Kruskal-
Wallis test (H-test). The Wilcoxon test (or Mann-Whitney U
test) for unpaired samples was applied to evaluate the sta-
tistical differences between two patient groups. Spear-
man's rank correlation analysis was performed to
determine statistical significance of differences between
two parameters in a classification group. P values equal or
less than 0.05 was regarded as significant.
Results
mRNA expression of eicosanoid receptors by real time 
PCR
Expression of leukotrienes and prostanoid receptors ana-
lyzed by quantitative real time PCR showed an up-regula-
tion of CysLT1  and CysLT2  receptors in CRS patients
compared to controls, but only CysLT1 was significantly
higher in CRS-NP in comparison to CRS patients as
showed in Figure 1a. EP2 and EP4 mRNA was up-regulated
in both CRS groups when compared with normal subjects
(Figure 1b). In contrast, EP1 and EP3 expression was simi-
lar in controls and CRS patients but significantly down-
regulated in the CRS-NP group (Figure 1b). Concentra-
tions of BLT1 and BLT2 receptors were similar in the three
groups of patients (data not shown).
Expression profile for the four EP and the two cysLTs
receptors analyzed in each individual group of patients is
illustrated in Figures 2 and 3. In the control group, expres-
sion of EP receptors did not show any differences. How-
ever, in the CRS and EP1 and EP3 receptors were down-
expressed compared to EP2 and EP4 and this difference
was more accentuated in the CRS-NP subjects. On the
other hand CysLT1 and CysLT2 mRNA levels were similar
in CRS and normal mucosa, however significantly higher
concentrations of CysLT1  compared to CysLT2  were
observed in the CRS-NP group.Respiratory Research 2006, 7:75 http://respiratory-research.com/content/7/1/75
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mRNA levels of eicosanoid receptors in nasalmucosa Figure 1
mRNA levels of eicosanoid receptors in nasalmucosa. a) cysLTs receptors, b) prostanoid-E receptors. Controls: healthy 
subjects, CRS: chronic rhinosinusitis, CRS-NP: chronic rhinosinusitis/nasal polyps. P: p value (unpaired Mann-Whitney U test).
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Balance of mRNA levels of prostanoid E receptors innasal  mucosa Figure 2
Balance of mRNA levels of prostanoid E receptors 
innasal mucosa. Controls: healthy subjects, CRS: chronic rhi-
nosinusitis, CRS-NP: chronic rhinosinusitis/nasal polyps. P: p 
value (unpaired Mann-Whitney U test).
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Eicosanoid levels and eosinophil inflammatory markers
Levels of eicosanoids and eosinophilic inflammatory
markers are summarized in table 2. While concentrations
of LTC4/D4/E4, were significantly higher in CRS-NP com-
pared to CRS and controls, no differences were observed
in LTB4 levels between the groups. PGE2 concentrations
however, were similar in CRS and control (p > 0.10) but
statistically lower in the nasal polyp tissue (p = 0.001).
Real time PCR for sol-IL-5α R showed a significantly
increase in CRS-NP subjects compared to CRS and in CRS
compared to control subjects. Accordingly, sol-IL-5Rα
protein was also statistically higher in the CRS-NP com-
pared to CRS and in this group compared to control tis-
sue. ECP was significantly increased in CRS compared to
the control group (p < 0.05) and even more in CRS-NP (p
< 0.02).
Immunohistochemistry results demonstrated a strong
infiltration of inflammatory cells in the nasal polyp com-
pared to the CRS and inferior turbinate tissues (data not
shown) and the median score for EG2 positive cells was
significantly higher in NP tissue compared to the control
and CRS tissues as summarized in Table 2.
The Spearman's rank correlation analysis showed a strong
correlation between both cysLTs receptors mRNA with
sol-IL-5Rα protein concentrations (CysLT1: rho = 0,574, p
= 0.01; CysLT2: rho = 0,523; p < 0.05), ECP (CysLT1: rho =
0,544, p = 0.02; CysLT2: rho = 0,413; p = 0.03) and the total
number of activated eosinophils (CysLT1: rho = 0,546, p =
0.02; CysLT2: rho = 0,614; p = 0.03). No correlations were
found between the levels of prostanoid receptors and
eosinophilic inflammation markers.
Immunohistochemical staining for prostanoid and 
leukotriene receptors
Immunohistochemical staining for CysLT1  and CysLT2
receptors in the nasal tissue is represented in Figure 3.
Immunoreactivity of both cysLTs receptors was observed
in inflammatory cells in the lamina propria in both CRS
groups. In addition, these receptors were expressed in the
sub-epithelial layer of the nasal mucosa and to a lesser
extend in the epithelium. Prostanoid-E receptors were
mainly expressed in the epithelium and in mucosal glands
(Figure 4). Immunoreactivity for EP2 and EP4 was higher
in inflammatory cells compared to epithelium, contrary
to EP1 and EP3 staining, which was localized mainly in
epithelial and sub-epithelial regions and blood vessels.
Discussion
Several studies have suggested changes in the eicosanoid
regulation patterns as one of the factors involved in the
pathophysiology of chronic rhinosinusitis and nasal poly-
posis; however, the effect of eicosanoids in the tissue,
greatly dependents of the differential expression of the
distinct subtypes of their receptors.
In this study, we confirmed that CysLT1 and CysLT2 recep-
tors are up-regulated in chronic rhinosinusitis and nasal
polyp patients. Interestingly, the balance of these recep-
tors was similar in healthy and chronic rhinosinusitis sub-
jects, in contrast to the nasal polyp group where
expression of CysLT1 was significantly higher when com-
pared to CysLT2. Furthermore, we evaluated the link
between these receptors and eosinophilic inflammation
and we observed that both CysLT1 and CysLT2 correlated
with markers of eosinophil activation like IL-5Rα, ECP
and the number of activated eosinophils. The data
obtained are in line with previous results showing that
Table 2: Concentration of eicosanoids and eosinophilic inflammation markers in chronic rhinosinusitis patients
Controls CRS CRS-NP Kruskall 
Wallis-test
Eicosanoids
LTC4/D4/E4 (ng/ml) 1.16 (IQR: 0.85–1.68) 3.34 (IQR: 2.70–5.35) 7.24 (IQR: 4.65–12.40) P < 0.01 §
LTB4 (ng/ml) 25.25 (IQR: 8.26–63.91) 21.95 (IQR: 9.40–31.90) 19.44 (IQR: 12.80–29.71) N.S
PGE2 (ng/ml) 180.63 (IQR: 101.44–258.86) 199.83 (IQR: 59.10–223.52) 55.00 (IQR: 40.59–67.87) p = 0.02 ¶
Eosinophilic inflammation markers
ECP (µg/L) 602.51 (IQR: 309.90–894.30) 2090.00 (IQR: 1437.60–5442.40) 11880.00 (IQR: 1862.70–17920.74) p < 0.01 §
Sol-IL-5Rα protein (ng/ml) 20.62 (IQR: 15.77–26.43) 50.95 (IQR: 28.62–67.78) 175.24 (IQR: 37.11–309.67) P < 0.05 §
sol-IL-5Rα mRNA (pg/µl) 14757.50 
(IQR: 12493.97–23015.35)
159065.30 
(IQR: 45909.00–185796.90)
458449.55 
(IQR: 267447.00–796387.30)
p = 0.02 §
EG2 positive cells 1,00 (IQR: 1,00–1,15) 1,05 (IQR: 1,00–1,40) 2,10 (IQR: 1,90–2,25) p < 0.01 ¶
Results are expressed as median and interquartile ranges (IQR). §: p < 0.05 is due to differences between the three sample groups; (¶): p < 0.05 is 
due to differences in the levels of CRS-NP versus controls and CRS patients. N.S: No statistical differences, p value > 0.05. CRS: chronic 
rhinosinusitis, CRS-NP: chronic rhinosinusitis/nasal polyp, Controls: healthy subjects.Respiratory Research 2006, 7:75 http://respiratory-research.com/content/7/1/75
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eosinophils are one of the most important sources of
these receptors in inflamed upper airways [20,21]; and
that CysLT1 maybe involved in several stages of eosinophil
differentiation, recruitment and maturation [22-24]. In
other hand, we did not found any changes in BLT recep-
tors expression between controls and disease groups.
These findings correspond with previous studies per-
formed in aspirin intolerant nasal polyp patients [25] and
with perennial allergic rhinitis [26]. However are in con-
trast with other reports showing increased levels of LTB4
and BLT receptors  in allergic versus non-allergic nasal
polyp patients [10]. Accordingly, there are no clear evi-
dences about the role of these molecules in chronic rhi-
nosinusitis and nasal polyposis and following our results,
we question its role in these diseases.
As well as leukotrienes, prostaglandins and especially
PGE2 play an important role in the regulation of the
inflammatory process observed in chronic rhinosinusitis
patients [27]. Little is known about the function and dis-
tribution of these receptors in airways and there are
almost no studies reporting the action or regulation of
Cysteinyl leukotriene receptors in chronicrhinosinusitis tissue Figure 4
Cysteinyl leukotriene receptors in chronicrhinosinusitis tissue. Representative photomicrography (original magnifica-
tion 40 ×) of chronic rhinosinusitis/nasal polyp specimens immunostained for CysLT1 and CysLT2 receptors in inflammatory 
cells, epithelium, glands and blood vessels.
CysLT1
CysLT2
Staining negative
control
Inflammatory cells
Epithelium and
subepithelium
Glands and blood 
vesselsRespiratory Research 2006, 7:75 http://respiratory-research.com/content/7/1/75
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Prostanoid E receptors in chronic rhinosinusitistissue Figure 5
Prostanoid E receptors in chronic rhinosinusitistissue. Representative photomicrography (original magnification 40 ×) 
of chronic rhinosinusitis/nasal polyp specimens immunostained for EP1, EP2, EP3 and EP4 receptors in inflammatory cells, epithe-
lium, glands and blood vessels.Respiratory Research 2006, 7:75 http://respiratory-research.com/content/7/1/75
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these receptors in upper airway tissue. We show with this
work that mRNA profile of prostanoid E receptors differs
between chronic rhinosinusitis with and without polyps,
again being different from healthy controls. We also
observed that EP2 and EP4 receptors are up-regulated in
chronic rhinosinusitis and nasal polyp tissue compared to
control subjects; however, EP1 and EP3 transcripts were
statistically decreased in the nasal polyp patients.
It has been reported, that action of agonists of EP1, EP4
and of a variant of EP3 is mediated by increase of intracel-
lular cAMP [28,29]. In inflammatory cells, this phenome-
non is associated with an inhibition of effector's cell
functions such as activation, or response to certain stimu-
lus [28,29]. Accordingly, we can assume that down-regu-
lation of these receptors may be related to an increase of
functionality or maybe susceptibility of inflammatory
cells to pro-inflammatory stimulus like IL-5 and leukot-
rienes contributing to the chronic inflammation observed
in chronic rhinosinusitis and even more in nasal polypo-
sis. However, and in contrast with the previous statement,
interaction of PGE2 with EP1 and EP3 variants is translated
in an increase of intracellular calcium, which can results in
an induction of immune cell activation [29]. This process
is of great importance in chronic rhinosinusitis/nasal
polyposis because increase of intracellular calcium may
induce the activation of cytosolic phospholipase A2 lead-
ing to the production of leukotrienes and other pro-
inflammatory lipid mediators again contributing to the
chronic inflammatory process observed in these diseases.
However, this is in contradiction with our results where
EP1 and EP3 are down- regulated in the disease groups.
Furthermore, an in vitro study performed on inflamma-
tory cells demonstrated that eosinophils express high lev-
els of EP2 and EP4 mRNA in comparison with EP1 and EP3,
which were almost not present in these cells and that defi-
ciency of PGE2 production may up-regulate the expression
of EP2 and EP4 molecules [30]. This is on line with our
findings however, mRNA levels of EP2 and EP4 receptors
did not correlate with eosinophil number or eosinophil
activation markers but it was increased in the disease
groups compared to controls. In addition, PGE2  was
down-regulated in chronic rhinosinusitis/nasal polyp tis-
sue compared to chronic rhinosinusitis and normal nasal
mucosa and the levels of this eicosanoid inversely corre-
lated to eosinophilic inflammation. Analysing closely
these results one may suggest that although synthesis of
PGE2 may be related to eosinophil activation, regulation
of its receptors at least at mRNA levels depends of mecha-
nisms involving other cellular sources as showed recently
by Ying and col. [15]. In addition, the lack of correlation
and the similar mRNA profile of these receptors between
the disease groups also suggest that functionality of these
receptors may greatly depend of post-transcriptional regu-
lation mechanisms. Here we were not able to analyze the
protein expression of these molecules to confirm our PCR
results but studies performed in nasal polyp patients par-
tially support this hypothesis [15].
Conclusion
mRNA pattern of eicosanoid receptors is different
between chronic rhinosinusitis and chronic rhinosinusi-
tis/nasal polyp patients and compared to healthy subjects.
CyLTs receptors are up-regulated in nasal polyp tissue and
correlate with eosinophilic inflammation supporting pre-
vious results. Eicosanoid receptors mRNA pattern
observed in our patient's groups suggest that down-regu-
lation of EP1 and EP3 in the nasal polyp tissue and up-reg-
ulation EP2 and EP4 in both chronic rhinosinusitis groups
may play a role in the development of the diseases and
their regulation do not directly depend of eosinophil acti-
vation. Furthermore, these results also suggest the impor-
tance of post-transcriptional events in the regulation of
receptor functionality involving other inflammatory mul-
tiple cellular sources. This is a descriptive preliminary
study, which opens the door to more specific experiments
including protein regulation, and functional studies that
will reveal more information about the role of these recep-
tors in chronic sinuses diseases.
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